NeuroSense: A Hold Ahead Of Phase 2b ALS Data (NASDAQ:NRSN)

Doctor in wit uniform met klinische stethoscoop houd streep blauw en wit lint bewustzijn met tekst stop ALS in de hand voor ALS of amyotrofische lateraal sclerose bewustzijn

Pornpak Khunatorn/iStock via Getty Images


NeuroSense (NRSN) is a microcap focused on the treatment of neurodegenerative diseases.

It is running a Phase 2b trial in 69 patients diagnosed with ALS, a fast-progressing neurodegenerative disease which is historically difficult to

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *